Any current/future new fundraising through debt or equity?

There is no explicit mention of any immediate or planned fundraising through debt or equity in the provided transcript. Abhay Soi mentions they are not raising any capital currently despite significant free cash flows (Rs. 1,281 crore free cash flows against Rs. 1,636 crore EBITDA). The company has a debt-free balance sheet. Abhay Soi states he would not shy away from diluting equity if there is a great growth opportunity like a merger or acquisition. They plan to redeploy all generated cash flows into the hospital sector for expansion, indicating organic growth funding rather than new fundrai

Any current/future capex/capital investment/strategic investment?

Routine CAPEX for FY24 is estimated at Rs. 170 crore, mainly for replacements in running hospitals. Capacity expansion CAPEX for ongoing projects is planned at Rs. 900 crore in FY24. Total network CAPEX includes Rs. 211 crore for routine maintenance and Rs. 208 crore for capacity expansion (ongoing projects). The company is fast-tracking construction on several key projects such as the 329-bed Nanavati hospital (commissioning expected by end FY25) and the 300-bed Gurgaon facility. Environmental clearance and other approvals are underway for the Vikrant site construction after delays at

Future growth expectations in sales/revenue/volumes?

Expect continued growth in Average Revenue Per Occupied Bed (ARPOB) driven by payor and specialty mix improvements and rising international business contribution. International business is growing strongly (10% quarterly growth, 43% YoY in FY23), with significant medium-term exponential growth potential. Institutional volume mix is expected to gradually decline from current levels due to capacity elasticity and pricing dynamics but won't hit 15% immediately. Operating at high occupancies (~77% overall, with some hospitals at 80-85%) suggests limited headroom for volume-driven growth; hen

Future growth expectations in earnings/operating earnings/profits/EPS?

Max Healthcare expects continued growth in EBITDA per bed, which is a key focus over operating margin, signaling overall earnings growth and improved ROCE. (Page 12) The company anticipates incremental growth in international patient business in FY24 and beyond, with medium-term exponential opportunities driven by India's comparative advantage. (Page 9) Free cash flows are strong, with Rs. 1,281 crore translating from Rs. 1,636 crore EBITDA, supporting reinvestment and capacity expansion without raising capital. (Page 5) Operating occupancy remains high (around 77%), providing scope for volume

Max Healthcare Institute LtdQ4 FY23Healthcare Services

Max Healthcare Institute Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,038P/E: 67.5Market Cap: ₹1.0L CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Expect continued growth in Average Revenue Per Occupied Bed (ARPOB) driven by payor and specialty mix improvements and rising international business contribution.
International business is growing strongly (10% quarterly growth, 43% YoY in FY23), with significant medium-term exponential growth potential.
Institutional volume mix is expected to gradually decline from current levels due to capacity elasticity and pricing dynamics but won't hit 15% immediately.
Operating at high occupancies (~77% overall, with some hospitals at 80-85%) suggests limited headroom for volume-driven growth; hence emphasis on revenue per bed and price increases (standard ~2-2.5% annually).
Expansion projects underway, including land acquisition for increasing beds and commissioning new hospitals by FY24-FY25 to grow capacity.
Digital revenue (~18% currently) continues to grow as a booking channel, but does not impact margins significantly.
Overall revenue growth driven by case mix, pricing, payor mix, and international patient inflow rather than just volume increases.

Margin guidance

Category 3

Max Healthcare expects continued growth in EBITDA per bed, which is a key focus over operating margin, signaling overall earnings growth and improved ROCE. (Page 12)
The company anticipates incremental growth in international patient business in FY24 and beyond, with medium-term exponential opportunities driven by India's comparative advantage. (Page 9)
Free cash flows are strong, with Rs. 1,281 crore translating from Rs. 1,636 crore EBITDA, supporting reinvestment and capacity expansion without raising capital. (Page 5)
Operating occupancy remains high (around 77%), providing scope for volume and revenue growth, though institutional bed share may stabilize below earlier targets. (Pages 3, 6, 21)
Margin expansion is driven by improved payor and case mix, as well as price increases—Q4 operating EBITDA margin was 28.2%, consistent with previous quarters. (Pages 3, 11)
Newly commissioned assets, like the oncology block at Max Shalimar Bagh, contributed EBITDA margins of 35-40%, indicating profitable growth from expansions. (Page 2)
Overall, Max Healthcare envisions multi-decade growth opportunities and aims for sustained improvement in earnings through cash flow reinvestment and strategic expansions. (Pages 4, 5, 21)

See what Max Healthcare Institute Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any immediate or planned fundraising through debt or equity in the provided transcript.
Abhay Soi mentions they are not raising any capital currently despite significant free cash flows (Rs. 1,281 crore free cash flows against Rs. 1,636 crore EBITDA).
The company has a debt-free balance sheet.
Abhay Soi states he would not shy away from diluting equity if there is a great growth opportunity like a merger or acquisition.
They plan to redeploy all generated cash flows into the hospital sector for expansion, indicating organic growth funding rather than new fundraising at present.
No ongoing or near-term debt or equity issuance is indicated in the transcript.

Order book

The transcript provided does not contain explicit information about the current or expected order book or pending orders for Max Healthcare Institute Limited. The discussion mainly revolves around: - EBITDA underwriting vis-à-vis PE firms. - Institutional volume mix trends. - Capacity expansion and bed unlocking plans. - Acquisition opportunities and expansion projects. - Price increases and improvements in ARPOB. - Growth prospects in international business. - Capital expenditure plans for FY24: ₹900 crore for ongoing projects and ₹170 crore as routine capex. No specific mention or data is given regarding current or expected order book or pending orders in the transcript on page 21 or surrounding pages.

See what Max Healthcare Institute Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Routine CAPEX for FY24 is estimated at Rs. 170 crore, mainly for replacements in running hospitals.
Capacity expansion CAPEX for ongoing projects is planned at Rs. 900 crore in FY24.
Total network CAPEX includes Rs. 211 crore for routine maintenance and Rs. 208 crore for capacity expansion (ongoing projects).
The company is fast-tracking construction on several key projects such as the 329-bed Nanavati hospital (commissioning expected by end FY25) and the 300-bed Gurgaon facility.
Environmental clearance and other approvals are underway for the Vikrant site construction after delays at Max Smart.
Management plans prudent evaluation and deployment of cash surplus from operations towards inorganic growth opportunities.
With Rs. 1,281 crore free cash flows from Rs. 1,636 crore EBITDA (approx. 80% EBITDA to free cash flow), the company foresees multi-decadal potential to keep investing without raising capital.

Track Max Healthcare Institute Ltd — get its next earnings analysis in your feed

Margin guidance

Category 3

Max Healthcare expects continued growth in EBITDA per bed, which is a key focus over operating margin, signaling overall earnings growth and improved ROCE. (Page 12)
The company anticipates incremental growth in international patient business in FY24 and beyond, with medium-term exponential opportunities driven by India's comparative advantage. (Page 9)
Free cash flows are strong, with Rs. 1,281 crore translating from Rs. 1,636 crore EBITDA, supporting reinvestment and capacity expansion without raising capital. (Page 5)
Operating occupancy remains high (around 77%), providing scope for volume and revenue growth, though institutional bed share may stabilize below earlier targets. (Pages 3, 6, 21)
Margin expansion is driven by improved payor and case mix, as well as price increases—Q4 operating EBITDA margin was 28.2%, consistent with previous quarters. (Pages 3, 11)
Newly commissioned assets, like the oncology block at Max Shalimar Bagh, contributed EBITDA margins of 35-40%, indicating profitable growth from expansions. (Page 2)
Overall, Max Healthcare envisions multi-decade growth opportunities and aims for sustained improvement in earnings through cash flow reinvestment and strategic expansions. (Pages 4, 5, 21)

Order book

How does Max Healthcare Institute Ltd rank vs peers in Healthcare Services?

Pro feature

ThisMax Healthcare Institute Ltd

Rev 3Mar 3

See where Max Healthcare Institute Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Max Healthcare Institute Ltd rank in Healthcare Services?

Compare Max Healthcare Institute Ltd against every Healthcare Services company (Q4 FY23) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Max Healthcare's management said in earlier quarters

Others in Healthcare Services this season

Metropolis Healt (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
Apollo Hospitals (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
Health X Platform (Q1 FY27)
July monthly revenue stood at INR 150+ crores, indicating strong growth momentum. Key concall takeaways from Health X Platform Ltd's Q1 FY27 earnings call…
Shalby (Q1 FY27)
Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase. Key concall takeaways from Shalby Ltd's Q1 FY27 earnings call — and how…

Compare:vs Apollo Hospitals vs Fortis Health.vs Aster DM Quality

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Max Healthcare Institute Ltd Q4 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Margin guidance

Order book

How does Max Healthcare Institute Ltd rank in Healthcare Services?

Continue your research

What Max Healthcare's management said in earlier quarters

Others in Healthcare Services this season